Emmaus Life Sciences, Inc. (EMMA)

Market Cap	5.36M
Revenue (ttm)	28.46M
Net Income (ttm)	-4.74M
Shares Out	53.64M
EPS (ttm)	-0.09
PE Ratio	n/a
Forward PE	1.63
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,635
Open	0.100
Previous Close	0.092
Day's Range	0.100 - 0.100
52-Week Range	0.051 - 0.340
Beta	1.70
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2019

About EMMA

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an a...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 54
• Stock Exchange: OTCMKTS
• Ticker Symbol: EMMA

Financial Performance

In 2022, EMMA's revenue was $18.39 million, a decrease of -10.77% compared to the previous year's $20.61 million. Losses were -$10.69 million, -32.99% less than in 2021.